Physiological Acclimatization of the Liver to 180-Day Isolation and the Mars Solar Day

被引:6
|
作者
Chen, Hailong [1 ]
Lv, Ke [1 ]
Ji, Guohua [1 ]
Yuan, Yanhong [1 ]
Lu, Liang [1 ]
Liang, Fengji [1 ]
Li, Kai [1 ]
Xu, Zi [2 ]
Xiong, Jianghui [1 ]
Qu, Lina [1 ]
Li, Yinghui [1 ]
机构
[1] China Astronaut Res & Training Ctr, State Key Lab Space Med Fundamentals & Applicat, 26 Beiqing Rd, Beijing, Peoples R China
[2] SPACEnter Space Sci & Technol Inst Shenzhen, Dept Hlth Technol Res & Dev, 4 Shamiao Rd,Pingdi St, Shenzhen 518117, Peoples R China
基金
中国国家自然科学基金;
关键词
PERIOD; ENTRAINMENT; METABOLISM; PACEMAKER; ENERGY;
D O I
10.1155/2020/2796510
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Physiological changes in humans are evident under environmental conditions similar to those on a Mars mission involving both a space factor (long-term isolation) and a time factor (the Mars solar day). However, very few studies have investigated the response of the liver to those conditions. Serum protein levels, bilirubin levels, aminotransferase activities, blood alkaline phosphatase, gamma-glutamyltransferase, lipid levels, and serum cytokines interleukin-6 and interferon-gamma levels were analyzed 30 days before the mock mission; on days 2, 30, 60, 75, 90, 105, 120, 150, and 175 of the mission; and 30 days after the mission, in four subjects in 4-person 180-day Controlled Ecological Life Support System Experiment. Serum protein levels (total protein and globulin) decreased and bilirubin increased under the isolation environment from day 2 and exhibited chronic acclimatization from days 30 to 175. Effects of the Mars solar day were evident on day 75. Blood lipid levels were somewhat affected. No obvious peak in any enzyme level was detected during the mission. The change tendency of these results indicated that future studies should explore whether protein parameters especially globulin could serve as indicators of immunological function exposure to the stress of a Mars mission.
引用
收藏
页数:7
相关论文
共 50 条
  • [22] A RANDOMIZED COMPARATIVE EFFECTIVENESS TRIAL OF A TRANSITIONAL CARE CLINIC: 180-DAY EFFECTS
    Liss, David T.
    Schaeffer-Pettigrew, Christine
    Finch, Emily
    Cooper, Andrew J.
    Sheth, Avani
    Tejuosho, Ashanti D.
    Teter, Caroline
    Ackermann, Ronald T.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 : S100 - S100
  • [23] Parity conditions and the efficiency of the Australian 90- and 180-day forward markets
    Felmingham, Bruce
    Leong, SuSan
    REVIEW OF FINANCIAL ECONOMICS, 2005, 14 (02) : 127 - 145
  • [24] Validation of a Machine Learning Algorithm to Predict 180-Day Mortality for Outpatients With Cancer
    Manz, Christopher R.
    Chen, Jinbo
    Liu, Manqing
    Chivers, Corey
    Regli, Susan Harkness
    Braun, Jennifer
    Draugelis, Michael
    Hanson, C. William
    Shulman, Lawrence N.
    Schuchter, Lynn M.
    O'Connor, Nina
    Bekelman, Justin E.
    Patel, Mitesh S.
    Parikh, Ravi B.
    JAMA ONCOLOGY, 2020, 6 (11) : 1723 - 1730
  • [25] 180-DAY TOLERANCE-EFFICACY STUDY WITH MIBOLERONE FOR SUPPRESSION OF ESTRUS IN CAT
    BURKE, TJ
    REYNOLDS, HA
    SOKOLOWSKI, JH
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 1977, 38 (04) : 469 - 477
  • [26] The Simple Math of Royalties and Drug Competition During the 180-Day Generic Exclusivity Period
    Drake, Keith M.
    McGuire, Thomas G.
    JOURNAL OF COMPETITION LAW & ECONOMICS, 2024, 20 (1-2) : 50 - 59
  • [27] Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment
    Bradley, Evan Stuart
    Howe, Emily
    Wu, Xun
    Haran, John P.
    GUT PATHOGENS, 2019, 11 (1)
  • [28] Developing a Machine Learning Model to Predict 180-day Readmission for Elderly Patients with Angina
    Luo, Yi
    Song, Xuewu
    Tong, Rongsheng
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2024, 25 (06)
  • [29] Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment
    Evan Stuart Bradley
    Emily Howe
    Xun Wu
    John P. Haran
    Gut Pathogens, 11
  • [30] Canadian competion during a US generic drug's 180-day exclusivity period
    Richard, K. M.
    Shepherd, M. D.
    VALUE IN HEALTH, 2007, 10 (06) : A361 - A362